Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-16
2005-08-16
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S260100, C514S274000, C544S253000, C544S278000, C544S309000, C544S314000
Reexamination Certificate
active
06930112
ABSTRACT:
Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and epileptogenesis. Methods for preparing the compounds of the invention are also described.
REFERENCES:
patent: 2461842 (1949-02-01), Olin
patent: 4255448 (1981-03-01), Fariello
patent: 4375477 (1983-03-01), Bey et al.
patent: 4703061 (1987-10-01), Kameyama et al.
patent: 4965283 (1990-10-01), Klessing et al.
patent: 5362902 (1994-11-01), Barnish et al.
patent: 5648369 (1997-07-01), Kadaba
patent: WO 98/40055 (1998-09-01), None
patent: WO 98/40055 (1998-09-01), None
El Nasser Ossman et al., Chemical Abstract 107:1689619k, 1987.
Bigge, C.F. et al. “Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: characterization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.”J. Med. Chem.38:3720-3740 (1995).
Ho, B. et al. “Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores.”Eur. J. Med. Chem.36:265-286 (2001).
Ling, R. et al., “Synthesis of 4-alkyl-pyrrolidine-3-carboxylic acid stereoisomers.”Tetrahedron57:6579-6588 (2001).
Abdul-Ghani, A. et al. “The Anti-Epileptic Effect of 3-Aminopropylarsonate on Electrically-Kindled and NMDA-Kindled Amygdala”Brain Research742(1-2):305-312 (1996).
Beyer, C. et al. “Prevention of the Convulsant and Hyperalgesic Action of Strychnine by Intrathecal Glycine and Related Amino Acids”Pharmacol Biochem Behav,29:73-78 (1988).
Bogousslavsky, J. et al. “Persistent Worsening of Stroke Sequelae After Delayed Seizures”Arch. Neurol.49:385-389 (1992). AMA Journals [online]. Chicago, IL, U.S.A.: Am. Med. Ass. [retrie-ved Sep. 13, 2000]. Dialog Information Services, Palo Alto, CA, USA, Dialog Acc No. 00055476.
Bonati, Chemical abstract 56:7247-7248 1962.
Camaggi, Chemical abstract 125:168644 1996.
Carran, John R. et al. “β-Amino Acids, a Novel Class of Antiictogenic/Antiepileptogenic Agents”Epilepsia39(Suppl. 6):40 (1998).
Fariello, R. “Action of Inhibitory Amino Acids on Acute Epileptic Foci: An Electrographic Study”Experimental Neurology66:55-63 (1979).
Gusel, V.A. “The Effects of GABA-Positive Drugs on the Primary and “Mirror” Epileptogenic Foci in the Rat Hippocamp”Farmakol Toksikol(USSR) 49(3):96-100 (1986) (Eng. Abstr. p. 100).
Horton, R. et al. “Convulsant and Anticonvulsant Actions in DBA/2 Mice of Compounds Blocking the Reuptake of GABA”European Journal of Pharmacology59:75-83 (1979).
Jefferys, J.G.R. “Nonsynaptic Modulation of Neuronal Activity in the Brain: Electric Currents and Extracellular Ions”Physiological Reviews75(4):689-723 (Oct. 1995).
Kouyoumdjian, J.C. et al. “Anticonvulsant Activity of Muscimol and γ-Aminobutyric Acid Against Pyridoxal Phosphate-Induced Epileptic Seizures”J Neurochem36(1):251-257 (1981).
Krogsgaard-Larsen, P. et al. “GABAAReceptor Agonists, Partial Agonists, and Antagonists. Design and Therapeutic Prospects”Journal of Medicinal Chemistry37(16):2489-2505 (1994).
Lambert, D.M. et al. “Dérivés simples d'acides aminés neurotransmetteurs. Evaluation anticonvulsivante de dérivés amides, carbamates et esters de la glycine et de la β-alanine”J. Pharm. Belg.50(2-3):194-203 (1995) (with English abstract on p. 194).
Leeson, P.D. et al. “The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential”Journal of Medicinal Chemistry37(24):4053-4067 (1994).
Liu, Q-R. et al. “Cloning and Expression of a cDNA Encoding the Transporter of Taurine and β-alanine in Mouse Brain”Proc. Natl. Acad. Sci. USA89:12145-12149 (1992).
Macon, JB. et al. “Responses of Somatosensory Cortial Neurons to Inhibitory Amino Acids During Topical and Iontophoretic Application of Epiletogenic Agents”Electroencephalography Clin.l Neurophysiol47:41-51 (1979).
Milne, PH. “The Design and Synthesis of Antiepileptic Agents Based on Neurotransmitter and Neural Metal-Mediated Inhibition”Disseration Abstracts International59/06-B:2767 (1998) (abstr) Diss. Abstr Online. Ann Arbor, MI, USA: University Microfilms International [retrieved on Sep. 13, 2000]. Dialog Information Services, Palo Alto, CA, USA. Dialog Acc. No 01650054.
Nanavati, S.M. et al. “Design of Potential Anticonvulsant Agents: Mechanistic Classification of GABA Aminotransferase Inactivators”Journal of Medicinal Chemistry32(11):2413-2421 (1989).
N'Goka, V. et al. “GABA-Uptake Inhibitors: Construction of a General Pharmacophore Model and Successful prediction of a New Representative”J. Med. Chem.34:2547-2557 (1991).
Okamoto, K. et al. “Effects of Amino Acids and Convulsants on Spontaneous Action Potentials in Cerebellar Cortex Slices”Br. J. Pharmac.57:3-15 (1976).
Paiva, M.Q. et al. “The Kinetic Characteristics of the Extraneuronal O-methlyating System of the Dog Sapherous Vein and the Supersensitivity to Cateholamines Caused by its Inhibition”Arch Pharmacol327:48-55 (1984).
Sangiah, S. “Effects of Glycine and Other Inhibitory Amino Acid Neurotransmitters on the Strychnine Convulsive Threshold in Mice”Vet. Hum. Toxicol.27(2):97-99 (1985).
Scanziani, M. et al. “Role of Excitatory Amino Acid and GABABReceptors in the Generation of Epileptiform Activity in Disinhibited Hippocampal Slice Cultures”Neurosci61(4):823-832 (1994).
Stasheff, Steven F. et al. “NMDA Antagonists Differentiate Epileptogenesis from Seizure Expression in an in Vitro Model”Science245:648-651 (Aug. 11, 1989).
Sur, R. N. et al. “Some Central Actions of β-Alanine”Indian Journal of Experimental Biology15:634-638 (1977).
Szkaradzinska, M.B. et al. “Two Cyclic Dipeptide Anticonvulsants: cyclo-Glycl-L-phenylglycine (1) and cyclo-L-Alanyl-D-phenylglycine (2)”Acta CrystallographicC50:565-569 (1994).
Testa, Chemical abstract 55:27004 1961.
Tsukada, Y. et al. “Suppressive Effects of Various Amino Acids against Ouabain-Induced Seizures in Rats”The Canadian Journal of Neurological SciencesNov.:214-221 (1974).
Watson, Craig “Status Epilepticus. Clinical Features, Pathophysiology, and Treatment”West J. Med:155:626-631 (Dec. 1991).
Wood, J.D. et al. “Comparison of GABA Uptake by Brain and Kidney Preparations”Amino Acids1:67-72 (1991).
Wu, F-S. et al. “Dual Activation of GABAAand Glycine Receptors by β-alanine: Inverse Modulation by Progesterone and 5α-pregnan-3α-ol-20-one”Eur J Pharmacol.246:239-246 (1993).
Carran John R.
Weaver Donald F.
DeConti, Jr. Esq. Guilio A.
Hanley, Esq. Elizabeth A.
Lahive & Cockfield LLP
Queen's University at Kingston
Rao Deepak
LandOfFree
Anti-epileptogenic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-epileptogenic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-epileptogenic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3484130